Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments

Circulation Research

Volumn 112, Issue 10, 2013, Pages 1334-1344

  Huke, Sabine ^a   Venkataraman, Raghav ^b   Faggioni, Michela ^a   Bennuri, Sirish ^a   Hwang, Hyun S ^a   Baudenbacher, Franz ^b   Knollmann, Björn C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Conduction velocity dispersion; Connexin 43; Familial hypertrophic cardiomyopathy; Myofilament Ca2+ sensitivity; Sudden cardiac death; Ventricular arrhythmias

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; BLEBBISTATIN; CALCIUM ION; CONNEXIN 43; ISOPRENALINE; LUCIFER YELLOW; CALCIUM; CARDIOTONIC AGENT; FUSED HETEROCYCLIC RINGS; QUINOLINE DERIVATIVE; THIADIAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANISOTROPY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENERGY EXPENDITURE; ENZYME ACTIVATION; GAP JUNCTION; HEART CONDUCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PACING; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOHISTOCHEMISTRY; MOUSE; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN LOCALIZATION; QRS COMPLEX; REENTRY TACHYCARDIA; SENSITIZATION; WESTERN BLOTTING; ANIMAL; CONDUCTION VELOCITY DISPERSION; DISEASE MODEL; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENERGY METABOLISM; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; FEMALE; HEART ARRHYTHMIA; MALE; METABOLISM; MOUSE STRAIN; MUSCLE FIBRIL; MYOFILAMENT CA2+ SENSITIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SUDDEN CARDIAC DEATH; TRANSGENIC MOUSE; VENTRICULAR ARRHYTHMIAS;

CONDUCTION VELOCITY DISPERSION; CONNEXIN 43; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; MYOFILAMENT CA2+ SENSITIVITY; SUDDEN CARDIAC DEATH; VENTRICULAR ARRHYTHMIAS;

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOTONIC AGENTS; CONNEXIN 43; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ELECTROCARDIOGRAPHY; ENERGY METABOLISM; FEMALE; GAP JUNCTIONS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MYOFIBRILS; QUINOLINES; THIADIAZINES;

MLCS; MLOWN;

EID: 84879812742     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.301055     Document Type: Article

References (70)

1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-789.
2. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008;5:158-168.
3. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858-864.
4. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36-44.
5. Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart. 2008;94:1269-1275.
6. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:1596-1601.
7. Theis JL, Bos JM, Theis JD, Miller DV, Dearani JA, Schaff HV, Gersh BJ, Ommen SR, Moss RL, Ackerman MJ. Expression patterns of cardiac myofilament proteins: genomic and protein analysis of surgical myectomy tissue from patients with obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 2009;2:325-333.
8. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315:610-614.
9. Semsarian C, French J, Trent RJ, Richmond DR, Jeremy RW. The natural history of left ventricular wall thickening in hypertrophic cardiomyopathy. Aust N Z J Med. 1997;27:51-58.
10. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.
11. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064-1075.
12. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.
13. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol. Cardiovasc Imaging. 2012; 5:370-377.
14. Huke S, Knollmann BC. Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. J Mol Cell Cardiol. 2010;48:824-833.
15. Knollmann BC, Potter JD. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2001;11:206-212.
16. Schober T, Huke S, Venkataraman R, Gryshchenko O, Kryshtal D, Hwang HS, Baudenbacher FJ, Knollmann BC. Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ Res. 2012;111:170-179.
17. Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ, Potter JD, Knollmann BC. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest. 2008;118:3893-3903.
18. Sims JJ, Miller AW, Ujhelyi MR. Electrical heterogeneity and arrhythmogenesis: importance of conduction velocity dispersion. J Cardiovasc Pharmacol. 2003;41:795-803.
19. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989;69:1049-1169.
20. Knollmann BC, Blatt SA, Horton K, de Freitas F, Miller T, Bell M, Housmans PR, Weissman NJ, Morad M, Potter JD. Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. J Biol Chem. 2001;276:10039-10048.
21. Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, Pauschinger M, Potter JD, Schultheiss HP, Tschöpe C. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail. 2006;8:115-121.
22. Knollmann BC, Kirchhof P, Sirenko SG, Degen H, Greene AE, Schober T, Mackow JC, Fabritz L, Potter JD, Morad M. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ Res. 2003;92:428-436.
23. Kléber AG. Gap junctions and conduction of cardiac excitation. Heart Rhythm. 2011;8:1981-1984.
24. Musil LS, Cunningham BA, Edelman GM, Goodenough DA. Differential phosphorylation of the gap junction protein connexin43 in junctional communication-competent and -deficient cell lines. J Cell Biol. 1990;111:2077-2088.
25. Solan JL, Lampe PD. Key connexin 43 phosphorylation events regulate the gap junction life cycle. J Membr Biol. 2007;217:35-41.
26. Solan JL, Lampe PD. Connexin43 phosphorylation: structural changes and biological effects. Biochem J. 2009;419:261-272.
27. Saffitz JE, Kanter HL, Green KG, Tolley TK, Beyer EC. Tissue-specific determinants of anisotropic conduction velocity in canine atrial and ventricular myocardium. Circ Res. 1994;74:1065-1070.
28. Spach MS, Heidlage JF, Dolber PC, Barr RC. Electrophysiological effects of remodeling cardiac gap junctions and cell size: experimental and model studies of normal cardiac growth. Circ Res. 2000;86:302-311.
29. Kaba RA, Coppen SR, Dupont E, Skepper JN, Elneil S, Haw MP, Pepper JR, Yacoub MH, Rothery S, Severs NJ. Comparison of connexin 43, 40 and 45 expression patterns in the developing human and mouse hearts. Cell Commun Adhes. 2001;8:339-343.
30. Smyth JW, Hong TT, Gao D, Vogan JM, Jensen BC, Fong TS, Simpson PC, Stainier DY, Chi NC, Shaw RM. Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium. J Clin Invest. 2010;120:266-279.
31. Beardslee MA, Lerner DL, Tadros PN, Laing JG, Beyer EC, Yamada KA, Kléber AG, Schuessler RB, Saffitz JE. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res. 2000;87:656-662.
32. Turner MS, Haywood GA, Andreka P, You L, Martin PE, Evans WH, Webster KA, Bishopric NH. Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels. Circ Res. 2004;95:726-733.
33. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003;144:5179-5183.
34. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem. 1996;271:27879-27887.
35. Frederich M, Balschi JA. The relationship between AMP-activated protein kinase activity and AMP concentration in the isolated perfused rat heart. J Biol Chem. 2002;277:1928-1932.
36. Baron SJ, Li J, Russell RR III, Neumann D, Miller EJ, Tuerk R, Wallimann T, Hurley RL, Witters LA, Young LH. Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circ Res. 2005;96:337-345.
37. Sovari AA, Iravanian S, Dolmatova E, Jiao Z, Liu H, Zandieh S, Kumar V, Wang K, Bernstein KE, Bonini MG, Duffy HS, Dudley SC. Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death. J Am Coll Cardiol. 2011;58:2332-2339.
38. Sosinsky GE, Solan JL, Gaietta GM, Ngan L, Lee GJ, Mackey MR, Lampe PD. The C-terminus of connexin43 adopts different conformations in the Golgi and gap junction as detected with structure-specific antibodies. Biochem J. 2007;408:375-385.
39. Ek-Vitorin JF, King TJ, Heyman NS, Lampe PD, Burt JM. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circ Res. 2006;98:1498-1505.
40. Lampe PD, TenBroek EM, Burt JM, Kurata WE, Johnson RG, Lau AF. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. J Cell Biol. 2000;149:1503-1512.
41. Morley GE, Vaidya D, Samie FH, Lo C, Delmar M, Jalife J. Characterization of conduction in the ventricles of normal and heterozygous Cx43 knockout mice using optical mapping. J Cardiovasc Electrophysiol. 1999;10:1361-1375.
42. Thomas SP, Kucera JP, Bircher-Lehmann L, Rudy Y, Saffitz JE, Kléber AG. Impulse propagation in synthetic strands of neonatal cardiac myocytes with genetically reduced levels of connexin43. Circ Res. 2003;92:1209-1216.
43. Eloff BC, Lerner DL, Yamada KA, Schuessler RB, Saffitz JE, Rosenbaum DS. High resolution optical mapping reveals conduction slowing in connexin43 deficient mice. Cardiovasc Res. 2001;51:681-690.
44. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation. 2000;101:547-552.
45. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J, Chien KR, Stuhlmann H, Fishman GI. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res. 2001;88:333-339.
46. Delmar M, Michaels DC, Johnson T, Jalife J. Effects of increasing intercellular resistance on transverse and longitudinal propagation in sheep epicardial muscle. Circ Res. 1987;60:780-785.
47. Dhein S, Krüsemann K, Schaefer T. Effects of the gap junction uncoupler palmitoleic acid on the activation and repolarization wavefronts in isolated rabbit hearts. Br J Pharmacol. 1999;128:1375-1384.
48. De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res. 2004;62:323-334.
49. Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Cardiac arrhythmogenesis and the gap junction. J Mol Cell Cardiol. 1995;27:37-44.
50. Hubbard ML, Henriquez CS. Microscopic variations in interstitial and intracellular structure modulate the distribution of conduction delays and block in cardiac tissue with source-load mismatch. Europace. 2012;14(Suppl 5):v3-v9.
51. Contreras JE, Sánchez HA, Eugenin EA, Speidel D, Theis M, Willecke K, Bukauskas FF, Bennett MV, Sáez JC. Metabolic inhibition induces opening of unapposed connexin 43 gap junction hemichannels and reduces gap junctional communication in cortical astrocytes in culture. Proc Natl Acad Sci USA. 2002;99:495-500.
52. Vergara L, Bao X, Cooper M, Bello-Reuss E, Reuss L. Gap-junctional hemichannels are activated by ATP depletion in human renal proximal tubule cells. J Membr Biol. 2003;196:173-184.
53. Oosthuyse T, Bosch AN. Oestrogen's regulation of fat metabolism during exercise and gender specific effects. Curr Opin Pharmacol. 2012;12:363-371.
54. Akingbemi BT. Adiponectin receptors in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci. 2013;114:317-342.
55. Schober T, Huke S, Venkataraman R, Gryshchenko O, Kryshtal D, Hwang HS, Baudenbacher FJ, Knollmann BC. Myofilament Ca2+ sensitization increases cytosolic Ca2+ binding affinity, alteres intracellular Ca2+ homeostasis and causes pause-dependent Ca2+ triggered arrhythmia. Circ Res. 2012; in revision.
56. Frey N, Brixius K, Schwinger RH, Benis T, Karpowski A, Lorenzen HP, Luedde M, Katus HA, Franz WM. Alterations of tension-dependent ATP utilization in a transgenic rat model of hypertrophic cardiomyopathy. J Biol Chem. 2006;281:29575-29582.
57. Rüegg JC, Strauss JD, Zeugner C, Trayer I. Effect of myosin heavy chain peptides on contractile activation of skinned cardiac muscle fibres. Adv Exp Med Biol. 1993;332:173-180; discussion 180.
58. Davies JE, Whinnett ZI, Francis DP, Manisty CH, Aguado-Sierra J, Willson K, Foale RA, Malik IS, Hughes AD, Parker KH, Mayet J. Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. Circulation. 2006;113:1768-1778.
59. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867-874.
60. Konno T, Chen D, Wang L, Wakimoto H, Teekakirikul P, Nayor M, Kawana M, Eminaga S, Gorham JM, Pandya K, Smithies O, Naya FJ, Olson EN, Seidman JG, Seidman CE. Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy. Proc Natl Acad Sci USA. 2010;107:18097-18102.
61. de Waard MC, van der Velden J, Bito V, Ozdemir S, Biesmans L, Boontje NM, Dekkers DH, Schoonderwoerd K, Schuurbiers HC, de Crom R, Stienen GJ, Sipido KR, Lamers JM, Duncker DJ. Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ Res. 2007;100:1079-1088.
62. Boontje NM, Merkus D, Zaremba R, Versteilen A, de Waard MC, Mearini G, de Beer VJ, Carrier L, Walker LA, Niessen HW, Dobrev D, Stienen GJ, Duncker DJ, van der Velden J. Enhanced myofilament responsiveness upon β-adrenergic stimulation in post-infarct remodeled myocardium. J Mol Cell Cardiol. 2011;50:487-499.
63. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002;87:169-176.
64. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, Thiene G, Iliceto S. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007;93:708-710.
65. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a firstin-man study. Lancet. 2011;378:667-675.
66. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010;3:522-527.
67. Dickstein K. Cardiac myosin activation: will theory and practice coincide? Lancet. 2011;378:639-641.
68. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562-1569.
69. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-1782.
70. Ferrantini C, Belus A, Piroddi N, Scellini B, Tesi C, Poggesi C. Mechanical and energetic consequences of HCM-causing mutations. J Cardiovasc Transl Res. 2009;2:441-451.